Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||APG-2575 + Palbociclib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|APG-2575||APG 2575|APG2575|Lisaftoclax||BCL2 inhibitor 24||APG-2575 is a small molecule that inhibits BCL-2, potentially resulting in increased apoptosis and enhanced antitumor activity in combination with other agents (Cancer Res July 1 2019 (79) (13 Supplement) 2058, PMID: 32093809).|
|Palbociclib||Ibrance||PD0332991||CDK4/6 Inhibitor 11||Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved in combination with an aromatase inhibitor in postmenopausal patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer, and in combination with Faslodex (fulvestrant) in patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04946864||Phase Ib/II||APG-2575 + Palbociclib APG-2575||A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer||Recruiting||USA||0|